Alnylam Pharmaceuticals, Inc. (ALNY) Q2 FY26 Earnings Call

AMVUTRA demand remains strong, but normalized second-line growth forced a $200 million midpoint guidance reduction.

Q2 FY26 results, source: company transcript and SEC filings
QuarterQ2 FY26
Call date2026-07-30
Length62 minutes
EPS$1.21
EPS consensus$1.44
Revenue$1.3B

What changed, guidance prior to now, analyst Q&A candor and the case for and against are part of Core.

Other quarters: Q2 FY25

All ALNY earnings ยท Back to ALNY overview

Transcript produced by Signals.AI from the company's own earnings call audio. Not personalized investment advice.